腎衰寧膠囊輔助治療慢性腎功能衰竭的療效觀察

馮躍華　王霄一

[摘要] 目的 探討腎衰寧膠囊輔助治療慢性腎功能衰竭的有效性及安全性。 方法 選擇2017年2月至2019年10月本院接受治療的慢性腎功能衰竭患者80例為研究對(duì)象，按照隨機(jī)數(shù)字表法分為觀察組與對(duì)照組，每組各40例。兩組患者均接受常規(guī)治療，對(duì)照組給予纈沙坦治療，觀察組在對(duì)照組基礎(chǔ)上給予腎衰寧膠囊輔助治療。比較兩組臨床治療有效率與不良反應(yīng)發(fā)生情況，同時(shí)觀察兩組治療前后腎功能指標(biāo)[血肌酐（Scr）、尿素氮（BUN）、尿白蛋白排泄率（UAER）]水平。 結(jié)果 治療4個(gè)月后，觀察組患者臨床治療有效率為92.50%，高于對(duì)照組的65.00%，差異有統(tǒng)計(jì)學(xué)意義（χ2=9.038，P<0.05）;治療前，觀察組患者Scr、BUN、UAER水平與對(duì)照組比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）;治療后，觀察組患者Scr、BUN水平低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）;觀察組患者不良反應(yīng)總發(fā)生率為7.50%，低于對(duì)照組的20.00%，但組間比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（χ2=2.635，P>0.05）。 結(jié)論 腎衰寧膠囊用于輔助治療慢性腎功能衰竭，療效顯著且安全。

[關(guān)鍵詞] 慢性腎功能衰竭;腎衰寧;腎功能;血肌酐

[中圖分類號(hào)] R692.5? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] B? ? ? ? ? [文章編號(hào)] 1673-9701（2021）20-0109-03

Observation of the efficacy of Shenshuaining capsule in adjuvant treatment of chronic renal failure

FENG Yuehua? ?WANG Xiaoyi

Department of Nephrology， the First People′s Hospital of Huzhou in Zhejiang Province， Huzhou? ?313000， China

[Abstract] Objective To explore the efficacy of Shenshuaining capsule in adjuvant treatment of chronic renal failure （CRF）. Methods From February 2017 to October 2019， a total of 80 patients with CRF treated in our hospital were selected as the subjects of research and were divided into the observation group and the control group according to random number table method， with 40 patients in each group. Both groups of patients received conventional treatment，the control group was treated with valsartan， and the observation group was administered Shenshuaining capsule as adjuvant treatment on the basis of the control group. The effective rate of clinical treatment and the occurrence of adverse reactions （ADRs） were compared between the observation group and the control group， and the levels of renal function indexes [serum creatinine （Scr）， blood urea nitrogen （BUN） and urinary albumin excretion rate （UAER）] in the two groups before and after treatment were observed. Results After 4 m of treatment， the effective rate of clinical treatment in the patients of the observation group was 92.50%， higher than the 65.00% in the patients of the control group， and the difference was statistically significant（χ2=9.038， P<0.05）. Before treatment，when comparisons were made between the patients of the observation group and the patients of the control group in terms of the levels of Scr， BUN and UAER， the differences were statistically insignificant（P>0.05）; after treatment， the levels of Scr and BUN in the patients of the observation group were lower than those in the patients of the control group， and the differences were statistically significant（P<0.05）;the total incidence of ADRs in the patients of the observation group was 7.50%， lower than the 20.00% in the patients of the control group， but the difference between the two groups was statistically insignificant（χ2=2.635， P>0.05）. Conclusion In adjuvant treatment of the patients with CRF， Shenshuaining can effectively improve the effective rate of clinical treatment and improve the renal function of the patients， and it has a certain safety.